Literature DB >> 1730465

Secretory immune responses to Mycoplasma pulmonis.

M J Steffen1, J L Ebersole.   

Abstract

Formalinized Mycoplasma pulmonis, along with aluminum hydroxide as an adjuvant, was used to subcutaneously immunize rats in the vicinity of the salivary gland to examine the characteristics of the secretory immune response to this pathogen. The induction of specific antibody to this microorganism was detected in serum and the exocrine fluids, namely, saliva and lung lavage fluid. Both immunoglobulin G (IgG) and IgA isotype antibodies were detected in each of these fluids after primary and secondary local immunizations. Serum responses from immunized animals were significantly greater than in the control group, but a dose response was not observed in either IgG or IgA antibody at the dosages selected for immunization. Salivary IgG antibody responses peaked early after both the primary and secondary immunizations, exhibiting a clear dose response. Salivary IgA in immunized groups was significantly greater than that in the control group but displayed little dose-dependent kinetics, and, at the termination of the experiment, this response had not yet peaked. Lung lavage IgG and IgA were minimal after the primary immunization when the antibody was normalized to total protein but displayed dose-dependent kinetics after a secondary challenge. IgG peaked immediately after a secondary challenge, while IgA peak responses were observed only after 20 days. A positive correlation was noted between the serum, saliva, and lung lavage fluid IgGs after both primary and secondary immunizations and only after a secondary challenge for IgA. In this study we were able to elicit a secretory immune response, consisting of both IgG and IgA, which exhibited a dose-dependent characteristic in lung lavage fluid to this immunogen. Additionally, a positive correlation of antibody levels between saliva and lung lavage fluid suggests that saliva could be used as an indicator for monitoring specific antibody to M. pulmonis in lung lavage secretions without requiring invasive, deleterious procedures.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1730465      PMCID: PMC257633          DOI: 10.1128/iai.60.2.337-344.1992

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  33 in total

1.  Aging effects on secretory IgA immune responses.

Authors:  J L Ebersole; M J Steffen
Journal:  Immunol Invest       Date:  1989 Jan-May       Impact factor: 3.657

2.  Establishment of an experimental model of a Staphylococcus aureus abscess in mice by use of dextran and gelatin microcarriers.

Authors:  C W Ford; J C Hamel; D Stapert; R J Yancey
Journal:  J Med Microbiol       Date:  1989-04       Impact factor: 2.472

3.  Effects of Lactobacillus casei on Pseudomonas aeruginosa infection in normal and dexamethasone-treated mice.

Authors:  H Saito; T Watanabe; Y Horikawa
Journal:  Microbiol Immunol       Date:  1986       Impact factor: 1.955

Review 4.  Immunoglobulin A (IgA): molecular and cellular interactions involved in IgA biosynthesis and immune response.

Authors:  J Mestecky; J R McGhee
Journal:  Adv Immunol       Date:  1987       Impact factor: 3.543

5.  Murine chronic respiratory disease. Significance as a research complication and experimental production with Mycoplasma pulmonis.

Authors:  J R Lindsey; H J Baker; R G Overcash; G H Cassell; C E Hunt
Journal:  Am J Pathol       Date:  1971-09       Impact factor: 4.307

6.  Serum antibody does not account for differences in the severity of chronic respiratory disease caused by Mycoplasma pulmonis in LEW and F344 rats.

Authors:  J W Simecka; J K Davis; G H Cassell
Journal:  Infect Immun       Date:  1989-11       Impact factor: 3.441

7.  Monoclonal antibody against pertussis toxin: effect on toxin activity and pertussis infections.

Authors:  H Sato; A Ito; J Chiba; Y Sato
Journal:  Infect Immun       Date:  1984-11       Impact factor: 3.441

8.  Enhanced murine respiratory tract IgA antibody response to oral influenza vaccine when combined with a lipoidal amine (avridine).

Authors:  K C Bergmann; R H Waldman
Journal:  Int Arch Allergy Appl Immunol       Date:  1988

9.  Differences in virulence for mice among strains of Mycoplasma pulmonis.

Authors:  M K Davidson; J R Lindsey; R F Parker; J G Tully; G H Cassell
Journal:  Infect Immun       Date:  1988-08       Impact factor: 3.441

10.  Protective immunity evoked by oral administration of attenuated aroA Salmonella typhimurium expressing cloned streptococcal M protein.

Authors:  T P Poirier; M A Kehoe; E H Beachey
Journal:  J Exp Med       Date:  1988-07-01       Impact factor: 14.307

View more
  2 in total

Review 1.  Mycoplasmas as Host Pantropic and Specific Pathogens: Clinical Implications, Gene Transfer, Virulence Factors, and Future Perspectives.

Authors:  Ali Dawood; Samah Attia Algharib; Gang Zhao; Tingting Zhu; Mingpu Qi; Kong Delai; Zhiyu Hao; Marawan A Marawan; Ihsanullah Shirani; Aizhen Guo
Journal:  Front Cell Infect Microbiol       Date:  2022-05-13       Impact factor: 6.073

2.  Mucosal and systemic immune responses to a recombinant protein expressed on the surface of the oral commensal bacterium Streptococcus gordonii after oral colonization.

Authors:  D Medaglini; G Pozzi; T P King; V A Fischetti
Journal:  Proc Natl Acad Sci U S A       Date:  1995-07-18       Impact factor: 11.205

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.